CTIS2022-500823-61-00进行中（未招募）1 期
A Phase 1/2 Study of BMS-986408 Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors - CA099-003
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 136
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Males or females = 18 years of age, Participants in Groups A and B must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy of any histology that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, and have received, be refractory to, ineligible for, or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant., Participants in Groups C, D and E must have a histologically or cytologically confirmed, advanced, unresectable/metastatic malignancy measurable by RECIST v1.1, with the following histologies: HNSCC, NSCLC, melanoma, or RCC, have previously received therapy containing anti-PD-(L)1 or anti-CTLA-4 agents, and have received, be refractory to, ineligible for, or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant.
排除标准
- •An active, known or suspected autoimmune disease, Conditions requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment, Current or recent gastrointestinal disease or gastrointestinal surgery that could impact the absorption of study drug, Untreated central nervous system (CNS) metastases or leptomeningeal metastasis, Women who are breastfeeding or are pregnant.
研究者
相似试验
招募中
1 期
A Phase 1/2 Study of BMS-986449 with and without Nivolumab in Participants with Solid TumorsAdvanced, metastatic, solid malignancyMedDRA version: 20.0Level: LLTClassification code: 10025648Term: Malignant mast cell tumors unspecified site extranodal and solid organ sites Class: 10029104CTIS2023-503484-42-00Bristol-Myers Squibb Services Unlimited Company98
招募中
1 期
A Phase 1b/2 Study of BMS-986442 with Nivolumab with or without Chemotherapy in Solid Tumors and Non-small Cell Lung CancerSolid Tumor, Non-small cell lung cancerMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2022-503108-26-00Bristol-Myers Squibb Services Unlimited Company245
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimumab in Patients with Advanced CancersEUCTR2018-000340-26-DEBristol-Myers Squibb International Corporation800
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimumab in Patients with Advanced CancersAdvanced solid tumorsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-509061-20-00Bristol Myers Squibb International Corporation639
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimumab in Patients with Advanced CancersAdvanced CancersMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2018-000340-26-PLBristol-Myers Squibb International Corporation800